類嗎啡類(opioids)成癮之療法，目前皆著重於以單一類嗎啡藥物來進行治療，然而影響其成癮之因素很多，其中精神因素即佔了重要的一部份，因此若能以治療精神疾病之藥物如選擇性血清素再回收抑制劑(selective serotonin reuptake inhibitors; SSRIs)來作為治療之藥物，將有可能加強減輕其戒斷症狀，提供另一治療之新選擇。
在給予不同之SSRIs時，其神經傳導物質及其代謝物之變化，各有所不同，然而目前則以sertraline所造成之含量變化和嗎啡較為類似，能有效增加各種神經傳導物質及其代謝物之含量， 為較有潛力成為治療類嗎啡類成癮之藥物。 The treatments of opioid addiction focus on the single use of opioids presently. However, there are many opioid addiction-associated factors, among which a psychological factor plays an important role. If selective serotonin reuptake inhibitors (SSRIs, a psychosis drug) are applied for an treatment, the withdrawal symptoms can be reduced and is another option to treat opioid dependence .
In this study, the efficacy and mechanism of SSRIs in reducing morphine-withdrawal symptoms were investigated. The study takes 2 years. In the first year, an animal model and the target neurotransmitter and metabolite levels in brain were set up by using microdialysis coupled with HPLC-ECD to evaluate the efficacy of SSRIs. In the second year, an estimative model was set up to discover the drugs.
A Simple high-performance liquid
chromatography with electrochemical detection using microdialysis was developed for simultaneous determination of monoamine neurotransmitters and metabolite levels in the rat corpus striatum. The detection limits of these compounds were 0.3-127nM, the correlation coefficients of regression were more than 0.99.
The method has been successfully applied to measure the neurotransmitters and their metabolite levels in the rat corpus striatum by morphine injection.
Each SSRI has different effects of neurotransmitter and metabolite levels in brain. But the effects of sertraline are more like to morphine, it can efficiently enhance the levels of neurotransmitters and their metabolite. Sertraline may be a candidate drug to treat opioid dependence.